Fibrogenesis resulting from cyclic bleeding: the Holy Grail of the natural history of ectopic endometrium
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
Despite the exponential growth in the number of PubMed-indexed publications on endometriosis in the last 60 years (Guo, 2014), a simple reality check can be quite humbling and, perhaps more likely, disheartening. Innovation drought is conspicuous. So far not a single biomarker has been proven to be clinically useful for diagnosing endometriosis (Gupta et al., 2016; Nisenblat et al., 2016a, 2016b). Furthermore, a good disease-staging system that correlates with the severity of symptoms and/or has prognostic predictive capability is lacking. The innovation drought is most glaring in the research and development of non-hormonal drugs: this is so painfully stagnant that the disappointment is audible (Vercellini et al., 2011). Currently, the top-of-the-line drug for treating endometriosis is dienogest; a drug that was originally synthesized by Jenapharm in then East Germany in the 1979 well before the boom of molecular biology of endometriosis and certainly before the advent of genomics or proteomics. Dienogest is effective in suppressing endometriosis-associated pain; however, it only alleviates symptoms, it does not reduce the volume of the endometriotic nodules (Leonardo-Pinto et al., 2017). While a new class of drug is now poised to get regulatory approval (i.e. gonadotropin-releasing hormone (GnRH) antagonists), it is far from innovative from the mechanism of action perspective even though it is structurally novel. GnRH antagonists still aims to modulate the hypothalamic–pituitary–gonadal (HPG) axis through a validated target, similarly to their agonist counterparts and, as such, may still share the same side-effects as GnRH agonists. Of course, GnRH antagonists can remove the ‘flare-up’ phenomenon, but their promise for more precise control of estrogen production could be undermined by the vast inter-individual variations. A search of ClinicalTrials.gov indicates that currently nine pharmaceutical companies are currently in the various stages of developing GnRH antagonists, making them the most coveted drug in reproductive medicine. Aside from GnRH antagonists, the research and development pipelines of all pharmaceutical companies seem to be trickling or are on the verge of drying up; several compounds in the Phase I stage appear to be congenitally ill-prepared to combat the fibroproliferative nature of endometriosis. No company is investing anything on drug research and development for adenomyosis, and so far all trials on non-hormonal drugs have apparently failed (Guo, 2014). Thus, it seems that in the next 5–8 years there will not be any truly revolutionary drug for patients with endometriosis or adenomyosis. This is a very serious problem. What went wrong? Faced with such an abject failure, one could still pretend that all is well, continue business as usual, wait for divine revelation, and pray that some miracles will happen eventually. Conscientious and responsible investigators, however, may experience bouts of self-doubt, do some soul-searching, and then contemplate possible paradigm shifts. Realistically, questioning the very basic that we have espoused so dearly that might have shackled our minds and imagination would be an easy and rational first step. Deceptively simple and straightforward, endometriosis has always been defined somewhat monolithically as ‘the presence of endometrial glands and stroma outside of the normal location’ (Beshay and Carr, 2012). However, this simple definition belies a kaleidoscopic variation in location, size, color, depth of invasion, presence or absence of adhesion, the proportion of epithelial/stromal cells, and even the presence or absence of these cell types, as in the well-documented phenomenon of ‘stromal endometriosis’ (i.e. lesions without glands) (Clement, 2007; Mai et al., 1997). On top of these variations, there is also a wild variation in symptomology and severity among patients. Dense fibrotic tissues are often present in and/or surrounding the lesions (Bonte et al., 2002; Clement, 2007; Cornillie et al., 1990; Guo et al., 2015; Itoga et al., 2003; Khare et al., 1996; Matsuzaki et al., 1999; Nisolle and Donnez, 1997; Stovall et al., 1992), especially in deep endometriosis (Bonte et al., 2002; Cornillie et al., 1990; Khare et al., 1996; Nisolle and Donnez, 1997). The fibrosis may result in subsequent adhesion, anatomic distortion and pelvic pain (Nisolle and Donnez, 1997). In this sense, the proposed redefinition of endometriosis by Dr Vigano and the famed Italian team in their Opinion article recently published in Human Reproduction is quite fitting and in fact long overdue (Vigano et al., 2017). With remarkable prescience, Vigano et al. rightly point out that a redefinition should reorient current research efforts towards more effective therapies, help to develop more adequate animal models for endometriosis and improve patient care (Vigano et al., 2017). Their proposal is all the more admirable at a time when one notable fad is to seek consensus on j
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the strength of estrogen signaling, in terms of estrogen production or ER activity, depends critically on the extent of lesional fibrosis, a proxy of the developmental stage of the lesions”
From Progressively diminished estrogen signaling concordant with increased fibrosis in ectopic endometrium (2025) · cites this paper as Guo, 2018
In the citing paper
“As adenomyosis shares with endometriosis in cyclic bleeding and thus ReTIAR”
From The Pathogenesis of Adenomyosis vis-à-vis Endometriosis (2020) · cites this paper as [104]
In the citing paper
“the notion that endometriotic lesions are wounds undergoing ReTIAR is only appreciated very recently21,22,53”
From Platelets induce increased estrogen production through NF-κB and TGF-β1 signaling pathways in endometriotic stromal cells (2020) · cites this paper as [53]
In the citing paper
“regardless of subtypes, all endometriotic lesions appear to undergo identical molecular processes such as epithelial-mesenchymal transition (EMT), fibroblast-to-myofibroblast transdifferentiation (FMT), smooth muscle metaplasia (SMM), and fibrogenesis25,26,53, even in adenomyotic lesions81,82.”
From Platelets induce increased estrogen production through NF-κB and TGF-β1 signaling pathways in endometriotic stromal cells (2020) · cites this paper as [53]
In the citing paper
“Thus, progressive EMT, FMT, SMM and fibrogenesis jointly constitute the natural history of endometriotic lesions27.”
From Neuropeptides Substance P and Calcitonin Gene Related Peptide Accelerate the Development and Fibrogenesis of Endometriosis (2019) · cites this paper as [27]
Citations
Cites
Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases
Wynn, T. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31487 · Cited by 1,456
Nisolle, M., & Donnez, J. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)00191-x · Cited by 1,279
Deeply infiltrating pelvic endometriosis: histology and clinical significance
Cornillie, F. J., Oosterlynck, D., Lauweryns, J. M., & Koninckx, P. R. (1990) · Fertility and Sterility · doi:10.1016/s0015-0282(16)53570-5 · Cited by 594
Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis
Walton, K. L., Johnson, K. E., & Harrison, C. A. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00461 · Cited by 543
Deep endometriosis: definition, diagnosis, and treatment
Koninckx, P. R., Ussia, A., Adamyan, L., Wattiez, A., & Donnez, J. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.07.1061 · Cited by 494
The pathophysiology of endometriosis and adenomyosis, tissue injury and repair
Leyendecker, G., Wildt, L., & Mall, G. (2009) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-009-1191-0 · Cited by 418
Blood biomarkers for the non-invasive diagnosis of endometriosis
Nisenblat, V., Bossuyt, P. M., Shaikh, R., Farquhar, C., Jordan, V., Scheffers, C. S., Mol, B. W. J., Johnson, N., & Hull, M. L. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012179 · Cited by 376
Guo, S.-W. (2009) · Molecular Human Reproduction · doi:10.1093/molehr/gap064 · Cited by 328
Self-citationClement, P. B. (2007) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3180ca7d7b · Cited by 320
Clement, P. B. (1990) · PubMed · Cited by 305
Research works printed but not linked: 1
- Beshay, 2012, Williams Gynecology, 281
Cited by
Rethinking mechanisms, diagnosis and management of endometriosis
Chapron, C., Marcellin, L., Borghese, B., & Santulli, P. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0245-z · Cited by 1,084
Pathogenesis of endometriosis: The genetic/epigenetic theory
Koninckx, P. R., Ussia, A., Adamyan, L., Wattiez, A., Gomel, V., & Martin, D. C. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.10.013 · Cited by 427
Hormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336
“Fibroblast–myofibroblast transdifferentiation contributes to collagen production and fibrogenesis [13], with entrapment of nerve fibers which, associated with chronic inflammation, explain pain symptoms.”
BackgroundEndometriosis: Cellular and Molecular Mechanisms Leading to Fibrosis
Garcia, J. M. G., Vannuzzi, V., Donati, C., Bernacchioni, C., Bruni, P., & Petraglia, F. (2022) · Reproductive Sciences · doi:10.1007/s43032-022-01083-x · Cited by 175
The Pathogenesis of Adenomyosis vis-à-vis Endometriosis
Guo, S.-W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020485 · Cited by 165
“For adenomyosis pathophysiology, the hypothesis of repeated tissue injury and repair (ReTIAR) has been proposed [104].”
BackgroundSelf-citation
Metadata
- Authors
- Guo, S.-W.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Corresponding author
- Guo, Sun-Wei
- ORCID
- Guo, Sun-Wei
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-06
- Volume
- 33
- Issue
- 3
- Pages
- 353-356
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2792621657
- Cited by
- 116
- References
- 46
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 13 · 2023: 19 · 2022: 14 · 2021: 15 · 2020: 20 · 2019: 8 · 2018: 4
- FWCI
- 12.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Human Reproduction (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Science Foundation of China
- Excellence in Centers of Clinical Medicine
- Science and Technology Commission of Shanghai Municipality
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Rheumatology › Heterotopic Ossification and Related Conditions
- Keywords
- ectopic endometrium, fibrogenesis, fibroproliferation, biomarkers, disease staging, GnRH antagonist, dienogest, endometriosis-associated pain, interindividual variability
- MeSH terms
- Endometriosis, Endometrium, Female, Fibrosis, Hemorrhage, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fibrogenesis resulting from cyclic bleeding: the Holy Grail of the natural history of ectopic endometrium. https://app.cochat.ai/papers/10.1093/humrep/dey015
- The paper
- Guo, S.-W. (2018). Fibrogenesis resulting from cyclic bleeding: the Holy Grail of the natural history of ectopic endometrium. Human Reproduction. https://doi.org/10.1093/humrep/dey015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.